Silke Hoersch
About
In The Last Decade
Silke Hoersch
16 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 1.1k
- Radiology, Nuclear Medicine and Imaging 471
- Pulmonary and Respiratory Medicine 459
- Cardiology and Cardiovascular Medicine 311
- Cancer Research 207
Countries citing papers authored by Silke Hoersch
This map shows the geographic impact of Silke Hoersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silke Hoersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silke Hoersch more than expected).
Fields of papers citing papers by Silke Hoersch
This network shows the impact of papers produced by Silke Hoersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silke Hoersch. The network helps show where Silke Hoersch may publish in the future.
Co-authorship network of co-authors of Silke Hoersch
This figure shows the co-authorship network connecting the top 25 collaborators of Silke Hoersch. A scholar is included among the top collaborators of Silke Hoersch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silke Hoersch. Silke Hoersch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 35 | |
| 2 | 79 | |
| 3 | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial breakdown → | 371 |
| 4 | 17 | |
| 5 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial breakdown → | 465 |
| 6 | 8 | |
| 7 | 5 | |
| 8 | 37 | |
| 9 | 194 | |
| 10 | 3 | |
| 11 | 16 | |
| 12 | 11 | |
| 13 | 74 | |
| 14 | 245 | |
| 15 | 1 | |
| 16 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.